Publication:
Author correction: combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma

dc.contributor.coauthorMazur PK, Herner A, Mello SS, Wirth M, Hausmann S, Sánchez-Rivera FJ, Lofgren SM, Kuschma T, Hahn SA, Vangala D, Trajkovic-Arsic M, Gupta A, Heid I, Noël PB, Braren R, Kleeff J, Sipos B, Sayles LC, Heikenwalder M, Heßmann E, Ellenrieder V, Esposito I, Jacks T, Bradner JE, Khatri P, Sweet-Cordero EA, Attardi LD, Schmid RM, Schneider G, Sage J, Siveke JT.
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.date.accessioned2024-12-29T09:38:59Z
dc.date.issued2024
dc.description.abstractIn the originally published version of this article, there were errors in the histological sections depicted in Supplementary Figs. 4 and 10. Specifically: In Supplementary Fig. 4, the image of the Ki67 immunohistochemistry (IHC) for the Gemcitabine+JQ1 group was incorrect In Supplementary Fig. 10, the pSTAT3 image for the IHC for the JQ1 group was incorrect In Supplementary Fig. 10, Ki67 and MYC IHC images for JQ1 and JQ1+SAHA were swapped In Supplementary Fig. 4, the image of the Ki67 immunohistochemistry (IHC) for the Gemcitabine+JQ1 group was incorrect In Supplementary Fig. 10, the pSTAT3 image for the IHC for the JQ1 group was incorrect In Supplementary Fig. 10, Ki67 and MYC IHC images for JQ1 and JQ1+SAHA were swapped The original data were available and these errors have been corrected in the Supplementary Information accompanying this notice. Additionally, the authors wish to clarify that the Sirius Red staining for the control and JQ1 groups were identical in both Supplementary Figs. 4 and 10 because the control mice (JQ1 only or control treatment) were shared between experiments. To avoid confusion, the sections depicting Sirius Red staining for the control and JQ1 groups in Supplementary Fig. 4 were replaced with alternative sections from the same respective samples
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue7
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume30
dc.identifier.doi10.1038/s41591-024-03054-y
dc.identifier.eissn1546-170X
dc.identifier.issn1078-8956
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85194734857
dc.identifier.urihttps://doi.org/10.1038/s41591-024-03054-y
dc.identifier.urihttps://hdl.handle.net/20.500.14288/22877
dc.identifier.wos1236066000001
dc.keywordsDrug therapy
dc.keywordsEpigenetics
dc.keywordsErratum
dc.keywordsHuman
dc.keywordsImmunohistochemistry
dc.keywordsIntravenous drug administration
dc.keywordsMajor clinical study
dc.keywordsMouse
dc.keywordsPancreatic ductal carcinoma
dc.keywordsPharmacokinetics
dc.keywordsSurgery
dc.keywordsTissue section
dc.keywordsDrug combination
dc.keywordsDrug interaction
dc.keywordsFemale
dc.keywordsTherapy
dc.language.isoeng
dc.publisherNature Research
dc.relation.ispartofNat Med
dc.subjectBiochemistry
dc.subjectMolecular biology
dc.subjectCell biology
dc.subjectMedicine
dc.subjectResearch
dc.subjectExperimental
dc.titleAuthor correction: combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
dc.typeOther
dc.type.otherCorrection
dspace.entity.typePublication
local.contributor.kuauthorErkan, Mert
local.publication.orgunit1KUH (KOÇ UNIVERSITY HOSPITAL)
local.publication.orgunit2KUH (Koç University Hospital)
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files